Paper314668
Monoclonal antibodies defining distinctive human T cell surface antigens.
Kung P and 3 others. Science, 1979. Cited by 1,674 papers, by iCite.
Cite this record
ConductScience Library. Monoclonal antibodies defining distinctive human T cell surface antigens. Papers, record 314668. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/314668
- Cell line
- OKT 34 papers
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records3
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antigens, Surface | Major topic |
| T-Lymphocytes | Major topic |
| Animals | |
| Antibody Specificity | |
| Cells, Cultured | |
| Clone Cells | |
| Humans | |
| Leukemia, Experimental | |
| Mice | |
| Plasmacytoma |
Source PubMed
Cited by347
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,674 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42255261 | Fully human anti-FOLR1 T-cell engager demonstrates potent activity in CBFA2T3::GLIS2 acute megakaryoblastic leukemia. | Blood Neoplasia | 2026 | https://conductscience.org/library/papers/42255261 | PubMed |
| 42156568 | Realizing the potential of agonistic antibody immunotherapy. | Nat Rev Drug Discov | 2026 | https://conductscience.org/library/papers/42156568 | PubMed |
| 42039438 | CELLISA - a cell-cell binding assay for evaluation of nanovesicle targeting proteins. | bioRxiv | 2026 | https://conductscience.org/library/papers/42039438 | PubMed |
| 42003454 | Taking the biology seriously makes models better. | Elife | 2026 | https://conductscience.org/library/papers/42003454 | PubMed |
| 41939869 | Evaluation of a reference antibody panel for prediction of cytokine release in humanised mouse models in vivo. | Front Immunol | 2026 | https://conductscience.org/library/papers/41939869 | PubMed |
| 41367414 | Integrative and Emerging Models in Antibody Research: A Comprehensive Review. | Antib Ther | 2025 | https://conductscience.org/library/papers/41367414 | PubMed |
| 40963254 | Adoptive transfer of NK cells engineered with a CD5-based chimeric antigen receptor (SRCD5CAR) to treat invasive fungal infections. | Mol Ther | 2025 | https://conductscience.org/library/papers/40963254 | PubMed |
| 40634636 | Beyond T-cell subsets: stemness and adaptation redefining immunity and immunotherapy. | Cell Mol Immunol | 2025 | https://conductscience.org/library/papers/40634636 | PubMed |
| 40143120 | Side Effects of Immunosuppressant Drugs After Liver Transplant. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40143120 | PubMed |
| 39990653 | Bispecific antibodies as powerful immunotherapeutic agents for urological cancers: Recent innovations based on preclinical and clinical evidence. | Int J Biol Sci | 2025 | https://conductscience.org/library/papers/39990653 | PubMed |
| 39584990 | A Brief Chronicle of Antibody Research and Technological Advances. | Antibodies (Basel) | 2024 | https://conductscience.org/library/papers/39584990 | PubMed |
| 39322753 | Benchmarking algorithms for single-cell multi-omics prediction and integration. | Nat Methods | 2024 | https://conductscience.org/library/papers/39322753 | PubMed |
| 39233453 | Animal models for transplant immunology: bridging bench to bedside. | Clin Transplant Res | 2024 | https://conductscience.org/library/papers/39233453 | PubMed |
| 38538786 | TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers. | Nature | 2024 | https://conductscience.org/library/papers/38538786 | PubMed |
| 38136728 | Antibiotic Resistance: Do We Need Only Cutting-Edge Methods, or Can New Visions Such as One Health Be More Useful for Learning from Nature? | Antibiotics (Basel) | 2023 | https://conductscience.org/library/papers/38136728 | PubMed |
| 37892982 | A History and Atlas of the Human CD4+ T Helper Cell. | Biomedicines | 2023 | https://conductscience.org/library/papers/37892982 | PubMed |
| 37508539 | Flow Cytometry: The Next Revolution. | Cells | 2023 | https://conductscience.org/library/papers/37508539 | PubMed |
| 36901797 | Aducanumab-Hope or Disappointment for Alzheimer's Disease. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36901797 | PubMed |
| 36831533 | Modulating T Cell Responses by Targeting CD3. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36831533 | PubMed |
| 35613320 | An adapted consensus protein design strategy for identifying globally optimal biotherapeutics. | MAbs | 2022 | https://conductscience.org/library/papers/35613320 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/314668
GET https://conductscience.org/api/papers/v1/314668/cited_by?page=2